Cytokinetics reports positive Phase 2 data for aficamten in nHCM; Phase 3 to start 2H 2023

CYTOKINETICS INC

At 10 weeks, aficamten improved KCCQ-CSS by 10.6 points (p<0.0001); 58% of patients had clinical symptom reduction.
56% of patients improved ≥1 NYHA class; 28% became asymptomatic (Class I) by Week 10.
Mean relative reductions: NT-proBNP 55% (p<0.0001) and high-sensitivity troponin I 21% (p<0.005).
In 14 patients with baseline angina, SAQ-AF score reduced 14.3 points (p=0.005), converting daily/weekly angina to weekly/monthly.
Aficamten well-tolerated; no discontinuations due to AEs, no LVEF<40%, and phase 3 trial planned for 2H 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.